Targeting Cognition in Bipolar Disorder With Pramipexole
Completed · Phase 4 · Has a placebo group
Conditions studied: Bipolar Disorder
In brief
Converging evidence suggests that patients with bipolar disorder suffer from deficits in neurocognitive functioning that persist, despite remission of acute affective symptoms. These impairments contribute directly to functional disability, highlighting the need for interventions above and beyond standard treatments in order to achieve a full inter-episode recovery. The current study aims to investigate the safety and efficacy of a dopamine agonist (pramipexole), on these persistent cognitive abnormalities in euthymic bipolar patients using a placebo-controlled, adjunctive, 12-week trial design.
Key facts
- Study ID
- NCT02397837
- Run by
- Brigham and Women's Hospital
- People needed
- 103
- Starts
- 2014-10-01
- Expected to finish
- 2018-07-26
- Last updated by the study team
- 2020-02-28
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18-65
- DSM-IV BD I or II diagnosis
- Affective stability, defined by a Young Mania Rating Scale (YMRS) rating of < 8 and a Hamilton Depression Rating Scale (HRSD) rating of < 16 at screening and baseline. We will further require that any subsyndromal depression has not significantly worsened in the 4 weeks prior to randomization so as to avoid enrolling subjects who are on the verge of a full depressive episode.
- Evidence of clinically-significant neurocognitive impairment at screening
- Clinically-acceptable, stably-dosed, mood stabilizing medication regimen for > 1 month prior to enrollment, with no medication changes planned over the 12-week study period.
You may not qualify if…
- History of CNS trauma, neurological disorder, ADHD, or learning disability
- Positive urine toxicology or DSM-IV diagnosis of substance abuse/dependence within 3 months
- Active, unstable medical problem that may interfere with cognition
- Recent history of rapid-cycling
- Abnormal lab or ECG result at screen
- History of heart failure
- Significant suicidal risk (HRSD item 3 > 2 or by clinical judgment)
- Estimated IQ in MR range as per Wide Range Achievement Test (WRAT) standard score of less than 70
- Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (including oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)
- Women who are breastfeeding
- Participation in any other investigational cognitive enhancement study within 30 days
Where it is running
- Brigham and Women's Hospital — Boston, Massachusetts, United States
- The Zucker Hillside Hospital — Glen Oaks, New York, United States
- Icahn School of Medicine at Mount Sinai — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.